Tyra Biosciences To Discuss Initial Clinical Results From SURF302 Phase 2 Study Evaluating Oral Dabogratinib For IR NMIBC In Conference Call And Webcast On September 9

뉴스 본문을 불러오고 있어요.

Tyra Biosciences To Discuss Initial Clinical Results From SURF302 Phase 2 Study Evaluating Oral Dabogratinib For IR NMIBC In Conference Call And Webcast On September 9 | 웨이프 WAPE

Tyra Biosciences To Discuss Initial Clinical Results From SURF302 Phase 2 Study Evaluating Oral Dabogratinib For IR NMIBC In Conference Call And Webcast On September 9

기사 요약

관련 종목

댓글 —